JavierMunozMDMS, FACP

Hematology • Phoenix, AZ

Hematologic Oncology

Director, Lymphoma Program at Mayo Clinic.

Join to view full profile

Dr. Munoz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Munoz's full profile

Already have an account?

Office
5881 E Mayo Blvd
Phoenix, AZ 85054
Phone+1 480-342-4800

Fax+1 480-301-4675

Summary

Dr. Munoz specializes in treating lymphomas and he is the Director of the Lymphoma Program at Mayo Clinic in Arizona. He is certified in Hematology and Medical Oncology. Dr. Munoz studied medicine in the “Universidad Peruana Cayetano Heredia” in Lima, Peru. Subsequently, he completed his residency and fellowship in Hematology-Oncology at Henry Ford Hospital in Michigan. Dr. Munoz also completed a Master of Science in patient-based research and an Investigational Cancer Therapeutics fellowship at the University of Texas MD Anderson Cancer Center in Houston before relocating to Arizona. Dr. Munoz also obtained an executive MBA in healthcare leadership and management for physicians from the University of Texas. He has been principal investigator in multiple cutting-edge lymphoma trials including immunotherapy and CAR T-cells. Within Mayo Clinic, Dr. Munoz is the Chair of the Feasibility Committee at a 3-site enterprise level, and the Associate Director of the Cancer Center Clinical Trials Office in Arizona. Dr. Munoz has published in internationally renowned journals including the New England Journal of Medicine, Nature Reviews, Blood, and JAMA. Dr. Munoz's personal goal is the development of non-chemotherapy agents, via novel clinical trials, to serve patients suffering with cancer.

ASH Choosing Wisely® Champions - Javier Munoz, MD

Javier Munoz, MD, of Banner MD Anderson Cancer Center in Gilbert, Arizona, was selected as one of the three inaugural ASH Choosing Wisely Champions

Movimiento en la búsqueda de una alternativa contra el cáncer

Investigaciones buscan una alternativa para tratar el cáncer, que incluso podría erradicarlo. Primer Impacto: Encuentra las noticias y reportajes más impactante

Why Watch and Wait Is Necessary

Why is the watch-and-wait period necessary for many people with chronic lymphocytic leukemia (CLL)? Dr. Javier Munoz

Education & Training

Henry Ford Health/Henry Ford HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011
Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 2005 - 2008
Cayetano Heredia UniversityClass of 2004
University of Texas M D Anderson Cancer CenterFellowship, Investigational Cancer Therapeutics Fellowship In Early Drug Development

Certifications & Licensure

AZ State Medical License 2012 - 2025
TX State Medical License 2011 - 2017
MI State Medical License 2005 - 2011
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

ASH Hematology Opportunities for the Next-generation of Research Scientists HONORS Award (Mentor) American Society of Hematology, 2019
Health Volunteers Overseas (HVO) American Society of Hematology, 2018
ASCO Virtual Mentoring Program American Society of Clinical Oncology, 2018
ASH Minority Resident Hematology Award Program (Mentor) American Society of Hematology, 2018
ASCO Diversity Mentoring American Society of Clinical Oncology, 2017
ASH Practice Partnership American Society of Hematology, 2017
40 under 40 Phoenix Business Journal, 2017
Choosing wisely champion American Society of Hematology, 2016
ASH Advocacy Leadership Institute American Society of Hematology, 2015
Join now to see all

Clinical Trials

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas Start of enrollment: 2012 Nov 19
Completed
Phase 2
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
Completed
Phase 3
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL Start of enrollment: 2013 Jun 13
Completed
Phase 1, Phase 2
A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2013 Nov 29
Completed
Phase 1, Phase 2
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL Start of enrollment: 2013 Aug 30
Completed
Phase 1, Phase 2
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Mar 13
Completed
Phase 1, Phase 2
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies Start of enrollment: 2014 Sep 04
Completed
Phase 1, Phase 2
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma Start of enrollment: 2015 Apr 21
Completed
Phase 1, Phase 2
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas Start of enrollment: 2016 Dec 01
Recruiting
Phase 2
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) Start of enrollment: 2015 Nov 09
Completed
Phase 2
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia Start of enrollment: 2016 May 11
Completed
Phase 1, Phase 2
Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma Start of enrollment: 2016 Aug 01
Completed
Phase 1
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product Start of enrollment: 2016 Oct 01
Terminated
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) Start of enrollment: 2017 Mar 02
Completed
Phase 2
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma Start of enrollment: 2017 Feb 28
Completed
Phase 2
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) Start of enrollment: 2017 Feb 15
Completed
Phase 1
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Start of enrollment: 2017 Jun 20
Active, not recruiting
Phase 2
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma Start of enrollment: 2017 Oct 04
Terminated
Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
Recruiting
Phase 1, Phase 2
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2018 Jan 25
Active, not recruiting
Phase 3
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) Start of enrollment: 2018 Jul 27
Completed
Phase 2
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) Start of enrollment: 2018 Oct 17
Recruiting
Phase 1, Phase 2
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Start of enrollment: 2019 Mar 08
Completed
Phase 1, Phase 2
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma Start of enrollment: 2018 Oct 15
Completed
Phase 1
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma Start of enrollment: 2019 Jan 29
Completed
Phase 2
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma Start of enrollment: 2019 May 01
Active, not recruiting
Phase 1
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma Start of enrollment: 2019 Nov 05
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

21 citations
Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Marc S Hoffmann, Bradley D Hunter, Patrick W Cobb, Juan C Varela, Javier Munoz
Transplantation and Cellular Therapy. 2023-07-01
81 citations
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
Jason R Westin, Olalekan O Oluwole, Marie José Kersten, David B Miklos, Miguel-Angel Perales
The New England Journal of Medicine. 2023-07-13
935 citations
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson
The New England Journal of Medicine. 2020-04-01

Abstracts/Posters

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with Rituximab
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell_like (Non-GCB) Diffus...
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and C...
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients...
Javier Munoz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
LBA-6 Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Z...
Sattva S. Neelapu, MD1, Frederick L. Locke, MD2, Nancy L. Bartlett, MD3, Lazaros Lekakis, MD4*, David Miklos, MD, PhD5, Caron A. Jacobson, MD6, Ira Braunschweig, MD7, ..., ASH - Late-Breaking Abstracts Session, San Diego USA, 12/6/2016
A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Ce...
Andre Goy, MD1, Radhakrishnan Ramchandren, MD2*, Nilanjan Ghosh, MD, PhD3, Javier Munoz, MD4, David S. Morgan, MD5, Nam H. Dang, MD, PhD6, Mark Knapp, MD7, Maria Delio..., ASH - Results from Prospective Clinical Trials, San Diego USA, 12/4/2016
Join now to see all

Lectures

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Reduction of Post-Treatment Scanning Using EMR Alerts
ASH San Diego 2016 - The ASH Choosing Wisely® Campaign: 2016 ASH Choosing Wisely Champions - 12/5/2016

Authored Content

CAR-T Cell Therapy Updates from TCT 2021February 2021

Press Mentions

Match Day Profile: Julie Tran and Diep NguyenMarch 18th, 2022
$Phase 2 Study of Parsaclisib (INCB050465), a Highly Selective, Next-Generation PI3Kδ Inhibitor, in Relapsed or Refractory Diffuse Large B-cell Lymphoma (CITADEL-202)$
Phase 2 Study of Parsaclisib (INCB050465), a Highly Selective, Next-Generation PI3Kδ Inhibitor, in Relapsed or Refractory Diffuse Large B-cell Lymphoma (CITADEL-202)November 3rd, 2020
Incidence and Clinical Presentation of MCLJanuary 30th, 2020
Join now to see all

Other Languages

Spanish

External Links

Mayo Clinichttps://www.mayoclinic.org/es/departments-centers/car-t-cell-therapy-program/home/orc-20404317
Programa de Células Thttps://vimeo.com/844033067/4b7f96380b?share=copy
Youtubehttps://www.youtube.com/watch?v=yVC6pCgE-Hw